Business
INOVIO Announces Pricing of $25 Million Public Offering
INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 13,158,000 shares of its common stock at a public offering price of $1.90 per share. All of the shares of common stock in the offering are being sold by INOVIO. The offering is expected to close on or about November 1
About this update from Inovio Pharmaceuticals, Inc.
[{"type":"text","content":"PLYMOUTH MEETING, Pa., Nov. 11, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 13,158,000 shares of its common stock at a public offering price of $1.90 per share. All of the shares of common stock in the offering are being sold by INOVIO. The offering is expected to close on or about November 12, 2025, subject to the satisfaction of customary closing conditions. INOVIO also granted the underwriters an option for a period of 30 days to purchase up to 1,973,700 additional shares of the Company's common stock at the public offering price, less the underwriting discounts and commissions.","length":867,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/INOVIO Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/INOVIO Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":129,"url":"https://media.zenfs.com/en/prnewswire.com/02f6eff2e3f0f811a2f544c30d57cb0d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Yd1bAc6HmDvRUbv9UGxnLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIyNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/02f6eff2e3f0f811a2f544c30d57cb0d","width":400,"height":129}},"href":"https://mma.prnewswire.com/media/2310866/INOVIO_v1_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by INOVIO, excluding any exercise of the underwriters' option to purchase additional shares of common stock, are expected to be approximately $25 million.","length":286,"tagName":"p"},{"type":"text","content":"Piper Sandler & Co. is acting as sole manager for the offering.","length":67,"tagName":"p"},{"type":"text","content":"A shelf registration statement relating to the shares of common stock offered in the offering described above was filed with the Securities and Exchange Commission ("SEC") on November 9, 2023 and declared effective by the SEC on January 31, 2024. The offering is being made only by means of a written prospectus...